Olaparib + Olaparib + Placebo + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Germline BRCA1/2 Mutations and
Conditions
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
Trial Timeline
Dec 16, 2014 → Jan 27, 2023
NCT ID
NCT02184195About Olaparib + Olaparib + Placebo + Placebo
Olaparib + Olaparib + Placebo + Placebo is a phase 3 stage product being developed by AstraZeneca for Germline BRCA1/2 Mutations and. The current trial status is completed. This product is registered under clinical trial identifier NCT02184195. Target conditions include Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02184195 | Phase 3 | Completed |
Competing Products
2 competing products in Germline BRCA1/2 Mutations and
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapy | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Olaparib | AstraZeneca | Phase 3 | 77 |